Marie Csete of AABB on AABB accreditation - at World Cord Blood Congress 2012
Marie Csete, Director of Cell Therapy at AABB, spoke at the World Cord Blood Congress 2012 on the topic, #39;AABB accreditation: a global approach to collaboration, innovation and quality. #39; World Cord Blood Congress is where private and public cord blood banks, pharma and biotechs, academia and government come to debate advances in cord blood banking and therapeutics. For more information, go to http://www.terrapinn.com/cordblood. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:21:41More inScience Technology

See original here:
Marie Csete of AABB on AABB accreditation - at World Cord Blood Congress 2012 - Video

Stem Cell Therapy at Integra Medical Center IMC
New Project 64From:OmarGonzalezMDViews:0 0ratingsTime:06:12More inScience Technology

Go here to read the rest:
Stem Cell Therapy at Integra Medical Center IMC - Video

Stem cell therapy procedure
This is a live video of stem cell therapy by intra-arterial procedure to a DMD patient. Muscualr Dystrophy Foundation India has been assisting patients in stem cell therapy in India. Please do visit http://www.mdfindia.orgFrom:MusclecampaignViews:2 0ratingsTime:01:39More inNonprofits Activism

Read more:
Stem cell therapy procedure - Video

PURTIER PRESENTATION
Please contact Mr.SAMSIUR SAUDJANA @ JAKARTA :+6281699062 Live cell therapy is a very effective stem cell therapy for improving health and even disease treatment other than for beauty and anti-aging.From:SAMSIUR SAUDJANAViews:1 0ratingsTime:09:00More inScience Technology

Read this article:
PURTIER PRESENTATION - Video

Donna Skerrett of Mesoblast on adult stem cell therapies - at Stem Cells USA RM Congress 2012
Donna Skerrett, Chief Medical Officer of Mesoblast, presented a case study on Mesoblast and their adult stem cell therapy at the Stem Cells USA Regenerative Medicine Congress 2012. The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:21:30More inScience Technology

Go here to see the original:
Donna Skerrett of Mesoblast on adult stem cell therapies - at Stem Cells USA

Animal Stem Cell Therapy
Dr Tim O #39;neill DVM hard at work showing you the amazing results of stem cell and Platlete Rich Plasma treatment.From:Greg SantiniViews:0 0ratingsTime:01:03More inPets Animals

Continued here:
Animal Stem Cell Therapy - Video

What Are Stem Cells - Mexico Specialist
http://www.mexicohealth.com The video shows a stem cell specialist from Mexico explaining in layman terms the stems cells and how they #39;re harvested. This specialist operates from Tijuana where he has been dedicated to finding a perfect recipe for different life threatening conditions and he has tasted success. With an astonishingly high initial response of over 80%, the doctor has cured over 40 patients for conditions like multiple sclerosis, brain damage, eye problems and cardiac problems. To get a free quote by Mexico specialist in stem cell therapy, click the link above. Related Searches: What are stem cells stem cell definitionFrom:mexicohealthViews:3 0ratingsTime:01:05More inPeople Blogs

Read more from the original source:
What Are Stem Cells - Mexico Specialist - Video

LEUVEN, BELGIUM and MADRID, SPAIN--(Marketwire - Dec 19, 2012) - TiGenix ( EURONEXT BRUSSELS : TIG ), the European leader in cell therapy, announced today positive interim safety results of its Phase IIa study of Cx611 in rheumatoid arthritis (RA). Cx611 is an intravenously injected suspension of expanded allogeneic adult stem cells derived from human adipose (fat) tissue. The Phase IIa clinical trial is a 53-subject, multicenter, placebo-controlled study in 3 cohorts with different dosing regimens, designed to assess safety, feasibility, tolerance, and optimal dosing. The study is being conducted at 23 centers. The Company believes that this clinical trial can set the stage not only for the further development of Cx611 in RA, but also in a wide range of other autoimmune disorders.

The interim results cover the first three months of the Phase IIa's six-month follow-up, and the data are still blinded. The primary endpoint of this study is safety, and the data collected so far support the good safety profile of all three doses of Cx611. Only two patients (4%) have suffered serious adverse events and only in one case (2%) it led to discontinuation of the treatment. All other side effects were mild and transient.

"We are delighted to report that the safety profile of Cx611 appears to be excellent," said Eduardo Bravo, CEO of TiGenix. "We have recruited patients who have failed at least two biologicals. If, in addition to this promising safety data, we can demonstrate a first indication of efficacy in this difficult to treat patient population, we will have a strong rationale to move forward with this product. We are looking forward to reporting the final results of the study at the end of April 2013."

About TiGenix

TiGenix NV ( EURONEXT BRUSSELS : TIG ) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit http://www.tigenix.com.

Forward-looking informationThis document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond TiGenix' control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in TiGenix' expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.

Link:
TiGenix: Positive Interim Safety Results of Phase IIa Rheumatoid Arthritis Study With Allogeneic Adult Stem Cells ...

When cosmetic surgeon Allan Wu first heard the woman's complaint, he wondered if she was imagining things or making it up. A resident of Los Angeles in her late sixties, she explained that she could not open her right eye without considerable pain and that every time she forced it open, she heard a strange clicka sharp sound, like a tiny castanet snapping shut. After examining her in person at The Morrow Institute in Rancho Mirage, Calif., Wu could see that something was wrong: Her eyelid drooped stubbornly, and the area around her eye was somewhat swollen. Six and a half hours of surgery later, he and his colleagues had dug out small chunks of bone from the woman's eyelid and tissue surrounding her eye, which was scratched but largely intact. The clicks she heard were the bone fragments grinding against one another.

About three months earlier the woman had opted for a relatively new kind of cosmetic procedure at a different clinic in Beverly Hillsa face-lift that made use of her own adult stem cells. First, cosmetic surgeons had removed some the woman's abdominal fat with liposuction and isolated the adult stem cells withina family of cells that can make many copies of themselves in an immature state and can develop into several different kinds of mature tissue. In this case the doctors extracted mesenchymal stem cellswhich can turn into bone, cartilage or fat, among other tissuesand injected those cells back into her face, especially around her eyes. The procedure cost her more than $20,000, Wu recollects. Such face-lifts supposedly rejuvenate the skin because stem cells turn into brand-new tissue and release chemicals that help heal aging cells and stimulate nearby cells to proliferate.

During the face-lift her clinicians had also injected some dermal filler, which plastic surgeons have safely used for more than 20 years to reduce the appearance of wrinkles. The principal component of such fillers is calcium hydroxylapatite, a mineral with which cell biologists encourage mesenchymal stem cells to turn into bonea fact that escaped the woman's clinicians. Wu thinks this unanticipated interaction explains her predicament. He successfully removed the pieces of bone from her eyelid in 2009 and says she is doing well today, but some living stem cells may linger in her face. These cells could turn into bone or other out-of-place tissues once again.

Dozens, perhaps hundreds, of clinics across the country offer a variety of similar, untested stem cell treatments for both cosmetic and medical purposes. Costing between $3,000 and $30,000, the treatments promise to alleviate everything from wrinkles to joint pain to autism. The U.S. Food and Drug Administration (FDA) has not approved any of these treatments and, with a limited budget, is struggling to keep track of all the unapproved therapies on the market. At the same time, pills, oils, creams and moisturizers that allegedly contain the right combination of ingredients to mobilize the body's resident stem cells, or contain chemicals extracted from the stem cells in plants and animals, are popping up in pharmacies and online. There's Stem Cell 100, for example, MEGA STEM and Apple Stem Cell Cloud Cream. Few of these cosmetics have been properly tested in published experiments, yet the companies that manufacture them say they may heal damaged organs, slow or reverse natural aging, restore youthful energy and revitalize the skin. Whether such cosmetics may also produce unintended and potentially harmful effects remains largely unexamined. The increasing number of untested and unauthorized stem cell treatments threaten both people who buy them and researchers hoping to conduct clinical trials for promising stem cell medicine.

When is a skin cream a drug? So far, the FDA has only approved one stem cell treatment: a transplant of bone marrow stem cells for people with the blood cancer leukemia. Among the increasing number of unapproved stem cell treatments, some clearly violate the FDA's regulations whereas others may technically be legal without its approval. In July 2012, for example, the U.S. District Court upheld an injunction brought by the FDA against Colorado-based Regenerative Sciences to regulate just one of the company's several stem cell treatments for various joint injuries as an "unapproved biological drug product." The decision hinged on what constitutes "minimal manipulation" of cells in the lab before they are injected into patients. In the treatment that the FDA won the right to regulate, stem cells are grown and modified in the lab for several weeks before they are returned to patients; in Regenerative Sciences's other treatments, patients' stem cells are extracted and injected within a day or two. Regenerative Sciences now offers the legally problematic treatment at a Cayman Island facility.

Many stem cell cosmetics reside in a legal gray area. Unlike drugs and "biologics" made from living cells and tissues, cosmetics do not require premarket approval from the FDA. But stem cell cosmetics often satisfy the FDA's definitions for both cosmetics and drugs. In September 2012 the FDA posted a letter on its Web site warning Lancme, a division of L'Oral, that the way it describes its Genifique skin care products qualify the creams and serums as unapproved drugs: they are supposed to "boost the activity of genes," for example, and "improve the condition of stem cells." Other times the difference between needing or not needing FDA approval comes down to linguistic nuancethe difference between claiming that a product does something or appears to do something.

Personal Cell Sciences, in Eatontown, N.J., sells some of the more sophisticated stem cellbased cosmetics: an eye cream, moisturizer and serum infused with chemicals derived from a consumer's own stem cells. According to its website and marketing materials, these products help "make skin more supple and radiant," "reduce the appearance of fine lines and wrinkles around the eyes and lips," "improve cellular renewal" and "stimulate cell turnover for renewed texture and tone." In exchange for $3,000, Personal Cell Sciences will arrange for a participating physician to vacuum about 60 cubic centimeters (one quarter cup) of a customer's fat from beneath his or her skin and ship it on ice to American CryoStem Corp. in Red Bank, N.J., where laboratory technicians isolate and grow the customer's mesenchymal stem cells to around 30 million strong. Half these cells are frozen for storage; from the other half, technicians harvest hundreds of different kinds of exuded growth factors and cytokinesmolecules that help heal damaged cells and encourage cells to divide, among other functions. These molecules are mixed with many other ingredientsincluding green tea extract, caffeine and vitaminsto create the company's various "U Autologous" skin care products, which are then sold back to the consumer for between $400 and $800. When the customer wants a refill, technicians thaw some of the frozen cells, collect more cytokines and produce new bottles of cream.

In an unpublished safety trial sponsored by Personal Cell Sciences, Frederic Stern of the Stern Center for Aesthetic Surgery in Bellevue, Wash., and his colleagues monitored 19 patients for eight weeks as they used the U Autologous products on the left sides of their faces. A computer program meant to objectively analyze photos of the volunteers' faces measured an average of 25.6 percent reduction in the volume of wrinkles on the treated side of the face. Analysis of tissue biopsies revealed increased levels of the protein elastin, which helps keep skin taut, and no signs of unusual or cancerous cell growth.

Only skin deep? Supposedly, the primary active ingredients in the U Autologous skin care products are the hundreds of different kinds of cytokines they contain. Cytokines are a large and diverse family of proteins that cells release to communicate with and influence one another. Cytokines can stimulate cell division or halt it; they can suppress the immune system or provoke it; they can also change a cell's shape, modulate its metabolism and force it to migrate from one location to another like a cowboy corralling cattle. Researchers have only named and characterized some of the many cytokines that stem cells secrete. Some of these molecules certainly help repair damaged cells and promote cell survival. Others seem to be involved in the development of tumors. In fact, some recent evidence suggests that the cytokines released by mesenchymal stem cells can trigger tumors by accelerating the growth of dormant cancer cells. Personal Cell Sciences does not pick and choose among the cytokines exuded by its customers' stem cellsinstead, it dumps them all into its skin care products.

Based on the available evidence so far, topical creams containing cytokines from stem cells pose far less risk of cancer than living stem cells injected beneath the skin. But scientists do not yet know enough about stem cell cytokines to reliably predict everything they will do when rubbed into the skin; they could interact with healthy skin cells in a completely unexpected way, just as the unintended interplay between calcium hydroxylapatite and stem cells produced bones in the Los Angeles woman's eye. Stern acknowledges that unusual tissue growth is a concern for any treatment based on stem cells and the chemicals they release. "Down the line, we want to continue watching that," he says. Unlike many other clinics, he and his colleagues have been keeping tabs on their patients through regular follow-ups. John Arnone, CEO of American CryoStem and founder of Personal Cell Sciences, says the fact that U Autologous skin care products contain such a diversity of cytokines does not bother him: "I've seen worse things out there. I've been putting this formulation for almost a year on myself prior to the study. I'm the best guinea pig here."

View post:
In the Flesh: The Embedded Dangers of Untested Stem Cell Cosmetics

Stem cell therapy True or fiction Dr. Ahmed korie alexandria university
Stem cell therapy True or fiction Dr. Ahmed korie alexandria universityFrom:mansvuViews:2 0ratingsTime:29:49More inEducation

Read this article:
Stem cell therapy True or fiction Dr. Ahmed korie alexandria university - Video

Stem Cell #39;s explained part 1 on The Susana Kennedy Show on 2oceansvibe
My ever increasing curiosity with the possibilities of Stem Cell therapy recently led me to meeting up with Dr. Duncan Carmichael from The Anti-Aging Clinic in Cape town, we chatted about what stem cell #39;s are, what some of the possibilities are and more, this is part one of a series of interviews I will be releasing over the next few weeks, demystifying the myths and revealing the incredible possibilities that are actually already available to you all right now. Enjoy!From:Susana KennedyViews:1 0ratingsTime:08:32More inScience Technology

Originally posted here:
Stem Cell's explained part 1 on The Susana Kennedy Show on 2oceansvibe - Video

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed an agreement with Octane Biotech of Kingston, Ontario, to jointly develop a proprietary bioreactor for production of its NurOwn stem cell therapy candidate. The customized bioreactor will enable BrainStorm to optimize its NurOwn production process, significantly increasing its production capabilities by using a single clean room for multiple patients, reducing costs and time. The project is supported by a grant awarded by the Canada-Israel Industrial Research and Development Foundation (CIIRDF).

Under the terms of the agreement, the companies will develop a commercially viable, safe, reliable, and cost-effective bioreactor for scale-up of BrainStorms NurOwn stem cell therapy, using Octanes Automated Cell & Tissue Engineering System (ACTES) technology. The CIIRDF funding award was approved for a period of three years.

Octane is the ideal partner for us, since they have a particular expertise in developing automated production processes for mesenchymal cell therapy technologies, commented Dr. Adrian Harel, BrainStorms CEO. We are anxious to move ahead with this project, in order to be in a position to provide NurOwn as quickly as possible, and to as many patients as possible, in the near future.

The opportunity to work with BrainStorm on scaling-up the NurOwn production process is a particularly meaningful one, given the urgency of its target population, said Dr. Tim Smith, Octanes CEO. We are confident that our combined knowledge base and commitment to the project will help advance their product significantly closer to clinical use.

BrainStorm is currently conducting a Phase I/II clinical trial in ALS patients at the Hadassah Medical Center in Jerusalem and is planning to expand its clinical development in the USA, pending FDA approval. Towards that goal, the Company has entered into a Memorandum of Understanding with the University of Massachusetts Medical School and Massachusetts General Hospital to begin ALS human clinical trials at these institutions.

About BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the companys website at http://www.brainstorm-cell.com.

About Octane Biotech

Octane develops innovative bioreactor-based systems to meet the production challenges inherent in the progressive scale-up of manual cell culture protocols. The companys unique Automated Cell & Tissue Engineering System (ACTES) solution integrates state-of-the-art bioreactors, biosensors and bioprocessing to enable routine GMP production of cell-based products for clinical therapeutics. Octane Biotech Inc. is one of three affiliated companies within the Octane Medical Group. For more information, visit the companys website at http://www.octaneco.com.

Read more from the original source:
BrainStorm and Octane to Develop Revolutionary Bioreactor-Based NurOwn Stem Cells Production Process

Genetic Engineering News

Epigenetics Underpins Homosexuality Genetic Engineering News Genetic Engineering & Biotechnology News | http://www.genengnews.com. Biotechnology from bench to business. Follow GEN on: Follow GEN on Facebook · Follow GEN on YouTube · Follow GEN on Twitter · Follow GEN on LinkedIn · Login | Register | Subscribe ... and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNH7cijlyqOuHbHTwuTz9STfzrQM8g&url=http://www.genengnews.com/gen-news-highlights/epigenetics-underpins-homosexuality/81247763/

Genetic Engineering News

Cliff Spells Danger for Biotechs Genetic Engineering News Genetic Engineering & Biotechnology News | http://www.genengnews.com. Biotechnology from bench to business. Follow GEN on: Follow GEN on Facebook Follow GEN on YouTube Follow GEN on Twitter Follow GEN on LinkedIn · Login | Register | Subscribe ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNF4P1b2fnxqUN8o_y924hIvW3Q8KQ&url=http://www.genengnews.com/insight-and-intelligence/cliff-spells-danger-for-biotechs/77899735/

New Times Broward-Palm Beach (blog)

Should Genetically Engineered Food Be Labeled? Florida Legislators Agree to ... New Times Broward-Palm Beach (blog) Since genetic engineering (GE) is not disclosed on product labels, consumers have no idea what kind of scientific tinkering has been done to those apples, oranges, or turkeys they're about to ingest. The folks behind Food & Water Watch want to change that. and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHWsdNuIcBSzIcVKe_m_elQ7emQgQ&url=http://blogs.browardpalmbeach.com/pulp/2012/11/genetically_engineered_food_florida.php

TheNewsTribune.com

N.C. Biotechnology Center awards $1.37 million in grants Winston-Salem Journal RESEARCH TRIANGLE PARK - The N.C. Biotechnology Center awarded Tuesday more than $1.37 million in grant awards for its first quarter for fiscal year 2012-13, or July through September. The awards went to institutions and organizations across the ... NC Biotech Center awards $1.37M in grants, other funding :: Editor's Blog at ...WRAL Tech Wire all 27 news articles »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHgLZh1-01gt9wGrAFMME02cplAhA&url=http://www.journalnow.com/business/business_news/local/article_03fbbafe-43fc-11e2-b001-0019bb30f31a.html

Globe and Mail

Genes Are Not The Only Drivers Of Colon Cancer Medical News Today ... and relapse. Dick, who is also a Professor in the Department of Molecular Genetics at the University of Toronto, says in a press statement that the study represents a "a major conceptual advance in understanding tumor growth and treatment response". Scientists Explore Resistance to Colon-Cancer TreatmentEndoNurse all 41 news articles »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFFVPFNEreuDw8TT0LmBJEybpgAew&url=http://www.medicalnewstoday.com/articles/254043.php

Prague Post

Of mice and men Prague Post In the south of Prague, the Institute of Molecular Genetics, part of the Academy of Sciences of the Czech Republic (AV?R), is building a vast resource of genetically engineered mice that enable scientists to analyze the function of individual genes.

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGDm4dAwcoK9QaBumgePEMrbNwSlg&url=http://www.praguepost.com/business/15022-of-mice-and-men.html

Cordis News

Health experts advocate implementing personalised medicine Cordis News ... Society and Brunel University (United Kingdom), Professor Angela Brand from the Institute for Public Health Genomics and Maastricht University (the Netherlands), and Professor Hans Lehrach from the Max Planck Institute for Molecular Genetics ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGW8BfeJiZJDY7Bh_y95Gka1ef43Q&url=http://cordis.europa.eu/fetch?CALLER%3DEN_NEWS%26ACTION%3DD%26SESSION%3D%26RCN%3D35343

For other things, however,  the people around you have such high expectations you'll do them that you only lose points if you don't but gain very little if you do.  For you, this may be true of the dishes.  Certainly I've always maintained this is true for Valentine's Day.  Get flowers and you simply maintain the relationship's status quo; fail to do anything and you lose big points fast.  

The result is "Why the stem cell sector must engage with social media".  What I attempted to succinctly outline are the ways social media primarily benefit one's career and organization or company.


"I can tell you without the slightest hesitation of conviction – having experienced it myself and seen it repeated countless times – is that active and successful social media engagement translates into:

• Unparalleled learning: accessing more information relevant to your discipline, specialty and company than you otherwise will. 
• Enhanced profile: higher profile within your industry, profession, specialty and community. Social media is not the only way to build a profile but it can be very effective.
• Wider network: more touch points and meaningful relationships with people than you otherwise will accomplish by any other means combined."

"In order to create the kinds of perceptions and solicit the kinds of actions we want from the world around us, we must engage the world around us. The world around us is engaging online. 

For all kinds of selfish and selfless reasons you, your company or organization and your career will benefit from you engaging there too."

and this prediction:

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/k7ANTnLXNjc/the-roi-on-pant-wearing-and-other.html